Williams Stephen B, Huo Jinhai, Chu Yiyi, Baillargeon Jacques G, Daskivich Timothy, Kuo Yong-Fang, Kosarek Christopher D, Kim Simon P, Orihuela Eduardo, Tyler Douglas S, Freedland Stephen J, Kamat Ashish M
Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX.
Department of Health Services Research, Management and Policy, The University of Florida, Gainesville, FL.
Urology. 2017 Dec;110:76-83. doi: 10.1016/j.urology.2017.08.024. Epub 2017 Aug 25.
To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations.
A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation.
Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively.
Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.
开发并验证一种用于评估根治性膀胱切除术后癌症及全因死亡率的列线图。鉴于对手术相关发病率的担忧,有必要将癌症特异性风险和竞争风险纳入患者咨询及建议中。
分别从监测、流行病学和最终结果 - 医疗保险(Surveillance, Epidemiology, and End Results-Medicare)以及德克萨斯癌症登记 - 医疗保险(Texas Cancer Registry-Medicare)关联数据中选取了2006年1月1日至2011年12月31日期间诊断为临床分期T2 - T4a肌层浸润性膀胱癌的5325例和1257例患者。使用Cox比例风险模型并开发列线图,以预测3年和5年的总生存率及癌症特异性生存率,并进行外部验证。
接受根治性膀胱切除术的患者大多较年轻、为男性、已婚、非西班牙裔白人,且合并症比未接受根治性膀胱切除术的患者少(P < 0.001)。与未婚患者相比,已婚患者的总生存率(风险比0.76;95%置信区间0.70 - 0.83,P < 0.001)和癌症特异性生存率(风险比0.76;95%置信区间0.68 - 0.85,P < 0.001)均有所提高。使用监测、流行病学和最终结果 - 医疗保险数据开发的列线图,在经过验证的德克萨斯癌症登记 - 医疗保险队列中,预测3年和5年总生存率及癌症特异性生存率的一致性指数分别为0.65和0.66。
年龄较大、未婚且合并症增加的患者接受根治性膀胱切除术的可能性较小。我们开发并验证了一种可推广的工具,该工具已转换为在线工具(根治性膀胱切除术生存计算器),为考虑接受根治性膀胱切除术的患者提供获益 - 风险评估。